Akumin Partners with Lunit to Leverage AI for Enhanced Breast Imaging Services Nationwide
Akumin, a prominent player in outpatient radiology and oncology services in the U.S., has made an impressive move forward by selecting Lunit INSIGHT DBT™, a pioneering AI technology designed for early breast cancer detection. This collaboration underscores Akumin's commitment to integrating advanced medical technologies that improve care delivery and enhance patient access to precision diagnostics.
Dr. Nasir Siddiqui, Chief Medical Officer at Akumin, expressed enthusiasm for the partnership, emphasizing that the AI solution aligns with the organization’s high standards for clinical excellence. By deploying Lunit INSIGHT DBT™, Akumin aims to make a significant impact on breast cancer detection and improve the experience of both patients and the radiologists who serve them. The technology has been validated through robust clinical trials and is supported by over 100 peer-reviewed research publications.
One of the key benefits of Lunit INSIGHT INSIGHT DBT™ is its FDA clearance for 2D and 3D imaging, which improves the ability to detect early-stage cancers while minimizing false positive results—issues that have long challenged healthcare providers. Given the rising demand for outpatient radiology and oncology services, healthcare providers are under immense pressure to expand access to these critical services. However, many face difficulties due to staffing shortages, increasing operational costs, and long construction timelines for in-house facilities.
In this context, Akumin’s extensive network—operating more than 150 fixed imaging sites across the nation—serves as a scalable solution. With their outpatient model, Akumin seeks to address the pressing challenges in diagnostic imaging by delivering timely, accessible imaging services without the need for healthcare facilities to incur the costs or challenges associated with building and staffing their own. Brandon Suh, CEO of Lunit, stated that Akumin's strategic investment in Lunit INSIGHT DBT™ supports a clinically evidence-based approach to resolving the ongoing hurdles in diagnostic imaging. As Lunit’s breast screening AI gains traction in over 200 imaging centers nationwide, it is evident that equipping radiologists with cutting-edge AI tools can substantially enhance patient outcomes through earlier detection and improved accuracy in cancer diagnosis.
With a rich history and experience in healthcare, Akumin collaborates with more than 1,000 healthcare providers, including 23 of the top 30 health systems in the U.S. Through a combination of advanced technology and clinical expertise, Akumin strives to foster greater patient access and elevate care standards across the healthcare landscape.
In summary, the partnership between Akumin and Lunit exemplifies a forward-thinking approach to tackle the growing demand for effective cancer detection services. With cutting-edge AI technology, both organizations are committed to pioneering a future where early cancer detection becomes more accessible and accurate for all patients. The collaboration not only promises to elevate clinical outcomes but also reflects a broader commitment to innovation within the healthcare industry. To learn more, visit Akumin's official website at www.akumin.com or delve into Lunit's vision at lunit.io.
Dr. Nasir Siddiqui, Chief Medical Officer at Akumin, expressed enthusiasm for the partnership, emphasizing that the AI solution aligns with the organization’s high standards for clinical excellence. By deploying Lunit INSIGHT DBT™, Akumin aims to make a significant impact on breast cancer detection and improve the experience of both patients and the radiologists who serve them. The technology has been validated through robust clinical trials and is supported by over 100 peer-reviewed research publications.
One of the key benefits of Lunit INSIGHT INSIGHT DBT™ is its FDA clearance for 2D and 3D imaging, which improves the ability to detect early-stage cancers while minimizing false positive results—issues that have long challenged healthcare providers. Given the rising demand for outpatient radiology and oncology services, healthcare providers are under immense pressure to expand access to these critical services. However, many face difficulties due to staffing shortages, increasing operational costs, and long construction timelines for in-house facilities.
In this context, Akumin’s extensive network—operating more than 150 fixed imaging sites across the nation—serves as a scalable solution. With their outpatient model, Akumin seeks to address the pressing challenges in diagnostic imaging by delivering timely, accessible imaging services without the need for healthcare facilities to incur the costs or challenges associated with building and staffing their own. Brandon Suh, CEO of Lunit, stated that Akumin's strategic investment in Lunit INSIGHT DBT™ supports a clinically evidence-based approach to resolving the ongoing hurdles in diagnostic imaging. As Lunit’s breast screening AI gains traction in over 200 imaging centers nationwide, it is evident that equipping radiologists with cutting-edge AI tools can substantially enhance patient outcomes through earlier detection and improved accuracy in cancer diagnosis.
With a rich history and experience in healthcare, Akumin collaborates with more than 1,000 healthcare providers, including 23 of the top 30 health systems in the U.S. Through a combination of advanced technology and clinical expertise, Akumin strives to foster greater patient access and elevate care standards across the healthcare landscape.
In summary, the partnership between Akumin and Lunit exemplifies a forward-thinking approach to tackle the growing demand for effective cancer detection services. With cutting-edge AI technology, both organizations are committed to pioneering a future where early cancer detection becomes more accessible and accurate for all patients. The collaboration not only promises to elevate clinical outcomes but also reflects a broader commitment to innovation within the healthcare industry. To learn more, visit Akumin's official website at www.akumin.com or delve into Lunit's vision at lunit.io.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.